Dr. Richard Davidson and Dr. Andrew Huberman discuss psychedelics for mental health, weighing therapeutic potential, risks, and the scientific context for responsible use

Psychedelics for mental health sit at the center of a discussion between Dr. Richard Davidson and Dr. Andrew Huberman, with emphasis on both therapeutic promise and meaningful risk. The focus is not on simple optimism, but on how altered states may affect depression, trauma, and emotional processing under specific conditions. Clinical benefits appear alongside cautions about set, setting, screening, and supervision. Risks can include psychological destabilization, adverse reactions, and misuse outside controlled environments, especially for vulnerable people or those with certain psychiatric histories. Scientific context matters because outcomes depend on dosage, preparation, support, and integration rather than on the substance alone. Responsible use therefore requires careful research, medical and ethical guardrails, and a clear distinction between emerging therapeutic models and unsupervised experimentation.